Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1195-1199

  Danowski, Adriana ^b   De Azevedo, Mario Newton Leitão ^a,b   Papi, Jose Angelo De Souza ^b   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Systemic lupus erythematosus; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ABORTION, HABITUAL; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERIES; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOPHILIA; TRIGLYCERIDES; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 67149087369     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081194     Document Type: Article

References (21)

1. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763 (Pubitemid 34983997)
2. Cervera R, Piette JC, Font J, et al, and the Euro-Phospholipid Project Group. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-1027
3. Somers E, Magder L, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-2536 (Pubitemid 35416957)
4. Wilson AW, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-1311
5. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi E. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003;12:302-307 (Pubitemid 36458661)
6. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus 1997;6:467-473 (Pubitemid 27395386)
7. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987;106:524-531
8. Turiel M. Thrombotic risk factors in primary antiphospholipid syndrome - a 5 year prospective study. Stroke 2005;36:1490-1494 (Pubitemid 40967518)
9. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian registry. Am J Med 1996;100:530-536 (Pubitemid 26170477)
10. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61:29-36.
11. McColl MD, Sattar N, Ellison J, et al. Lipoprotein(a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000;11:225-229 (Pubitemid 30331800)
12. Vaya A, Mira Y, Ferrando F, et al. Hyperlipaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002;118:255-259 (Pubitemid 34779546)
13. Brouwer JLP, Biji M, Veeger NJGM, Kluin-Nelemans HC, Van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-148 (Pubitemid 38879850)
14. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-1124 (Pubitemid 26358611)
15. Martinez-Berrotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2004;13:927-933 (Pubitemid 39664952)
16. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720-2726 (Pubitemid 44917549)
17. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008;300:795-804.
18. Gris JC, Perneger TV, Quéré I, et al. Antiphospholipid / antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003;102:3504-3513 (Pubitemid 37409365)
19. Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002;187:1337-1342 (Pubitemid 35397483)
20. Del Bianco A, Maruotti G, Fulgieri AM, et al. Recurrent spontaneous miscarriages and hyperhomocysteinemia. Minerva Ginecol 2004;56:379-383 (Pubitemid 40039212)
21. Raziel A, Kornberg Y, Friedler S, Schater M, Sela BA, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol 2001;45:65-71. (Pubitemid 32111900)